Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 8/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415042 | 0.88 | VCP (0.48) | VCPNPY5RHRH4 | |
| SCHEMBL3005238 | 0.88 | NPY5R (0.45) | NPY5R | |
| SCHEMBL3009562 | 0.87 | VCP (0.43) | VCPNPY5RBRD4ATAD2HRH4 | |
| SCHEMBL3008520 | 0.86 | NPY5R (0.48) | NPY5R | |
| SCHEMBL3000216 | 0.86 | NPY5R (0.50) | NPY5RBRD4ITK | |
| SCHEMBL2999762 | 0.86 | BRD4 (0.48) | NPY5RBRD4ATAD2ITK | |
| SCHEMBL3004440 | 0.85 | CSF1R (0.48) | NPY5RBRD4ATAD2 | |
| Hydrochloric Acid SCHEMBL3415428 | 0.85 | BRD4 (0.47) | NPY5RBRD4ATAD2ITK | |
| SCHEMBL3012816 | 0.84 | ALDH1A1 (0.43) | VCPNPY5RBRD4ATAD2ITK | |
| SCHEMBL2999826 | 0.83 | VCP (0.40) | VCPNPY5RBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | claimed |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-02-05 | — | — | US | claimed |
| CN-101952281-B | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD | 2014-04-02 | — | — | CN | claimed |
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | claimed |
| CN-101784543-B | Indole and indazole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2013-10-16 | — | — | CN | claimed |
| US-8436038-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-05-07 | — | — | US | claimed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | claimed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | claimed |
| CN-101952281-A | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD | 2011-01-19 | — | — | CN | claimed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | claimed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | claimed |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2010-08-05 | — | — | US | claimed |
| CN-101784543-A | Indole and indazole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2010-07-21 | — | — | CN | claimed |
| EP-2178870-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009025478-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | claimed |
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | disclosed |
| US-9000028-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2015-04-07 | — | — | US | disclosed |
| WO-2009088192-A9 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | 주식회사 엘지생명과학 (KR) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009088192-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009025478-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | VCP 4243/4885NPY5R 1549/4885BRD4 1985/4885 |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, NFATC1 | VCP 3548/4885NPY5R 2110/4885BRD4 1492/4885 |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | AQP1, EYA3, SF1 | VCP 2813/4885NPY5R 3163/4885BRD4 4563/4885 |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | VCP 4243/4885NPY5R 1549/4885BRD4 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.